Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamine therapy (licensed doses).
Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report 1
- M. Maurer, K. Weller, T. Zuberbier
- MedicineAllergy. European Journal of Allergy and Clinical…
- 1 March 2011
A GA2LEN task force report concluded that chronic spontaneous urticaria is a “hidden epidemic” that needs to be addressed to address the unmet clinical needs of patients.
A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis.
This classification aid serves as a basic introduction into the field ofhair follicle morphogenesis, aims at standardizing the presentation of related hair research data, and should become a useful tool when screening new mouse mutants for discrete abnormalities of hair follicles morphogenesis in a highly reproducible, easily applicable, and quantifiable manner.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Mast Cells Can Secrete Vascular Permeability Factor/ Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release after Immunoglobulin E–dependent Upregulation of Fcε Receptor I Expression
It is reported here that mouse or human mast cells can produce and secrete VPF/VEGF, and a new mechanism by whichmast cells can contribute to enhanced vascular permeability and/or angiogenesis, in both allergic diseases and other settings.
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
WAO Guideline for the Management of Hereditary Angioedema
- T. Craig, Emel Aygören Pürsün, M. Maurer
- MedicineThe World Allergy Organization Journal
- 1 December 2012
A group of specialists that focus upon HAE from around the world to develop not only a consensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus meets criteria as a guideline.
Schnitzler's syndrome: diagnosis, treatment, and follow‐up
First‐line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra and follow‐up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.
Pharmacology of Antihistamines
All H1-antihistamines have anti-inflammatory effects but it requires regular daily dosing rather than dosing 'on-demand' for this effect to be clinically demonstrable.
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European…